Habib Bennaceur: Novo Nordisk Completed its Acquisition of Zaltenibart from Omeros Corporation
Habib Bennaceur, SVP Rare Disease Unit at Novo Nordisk, shared on LinkedIn:
”I am pleased to share that Novo Nordisk completed its acquisition of zaltenibart from Omeros Corporation strengthening our commitment to address unmet needs in rare blood and kidney disorders.
This addition expands our portfolio in haematology and renal as we continue working to serve more people and communities living with rare diseases.
Zaltenibart is an investigational antibody designed to precisely target MASP-3 in the complement system, representing a novel mechanism of action for our haemato-renal portfolio.
Early clinical data in paroxysmal nocturnal haemoglobinuria (PNH) is encouraging, and we look forward to advancing zaltenibart’s development and exploring its potential to provide new treatment options as we drive lasting change in rare disease.”
Stay updated with Hemostasis Today.
-
Jan 16, 2026, 13:15Paul Bolaji Invites You to Join World Stroke Organization Membership
-
Jan 16, 2026, 12:59Prithu Sundd on The Role of CD39 Polymorphism in Enabling Pulmonary Thrombosis in SCD
-
Jan 16, 2026, 12:46Gregory Piazza on The Effect of Enduring Risk Factors in Provoked VTE
-
Jan 16, 2026, 12:33Fernando Corrales-Medina on Heavy Periods in Teens: Don’t Miss a Bleeding Disorder
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor